CAS: 320367-13-3; Lixisenatide

主要参考文献

1: Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. 2012–. Lixisenatide. 2019 Apr 10. 59(1513):19-21. 52(1):65-80. doi: 10.1310/hpj5201-65.
5: Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo- controlled trial. Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869. doi: 10.1016/S2213-8587(18)30268-7. Epub 2018 Oct 3. 2006–. Lixisenatide. 2018 Dec 3. 51(5):401-409. doi: 10.1177/1060028017689878. Epub 2017 Jan 29. 104(2):359-368. doi: 10.1210/jc.2018-01176.
9: Cai X, Gao X, Yang W, Ji L. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017 Dec;18(17):1789-1798. doi: 10.1080/14656566.2017.1400011. Epub 2017 Nov 5. LixiLan-O Trial Investigators. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15. Erratum in: Diabetes Care. 2017 Jun;40(6):809.

合成参考文献

参考文献:10.2337/dc16-2143
摘要:Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, Manrique Hurtado H, Guo H, Pilorget V, Perfetti R, Simpson H; GetGoal-O Trial Investigators. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. Diabetes Care. 2017 Apr;40(4):485–93. doi: 10.2337/dc16-2143.
参考文献:10.1111/dom.12911
摘要:Albèr A, Brønden A, Knop FK. Short‐acting glucagon‐like peptide‐1 receptor agonists as add‐on to insulin therapy in type 1 diabetes: A review. Diabetes Obesity Metabolism. 2017 Mar 17;19(7):915–25. doi: 10.1111/dom.12911.
参考文献:10.1016/j.taap.2017.02.010
摘要:van den Brink W, Emerenciana A, Bellanti F, Della Pasqua O, van der Laan JW. Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents. Toxicol Appl Pharmacol. 2017 Apr 01;320():51–9. doi: 10.1016/j.taap.2017.02.010.
摘要:Wynn P. NEW FOR YOU! These innovative products aim to help make diabetes self-management easier. Diabetes Self Manag. 2017 Mar;34(2):24–7, 31.